Novartis' lung cancer drug gets breakthrough designation

03/19/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy status to Novartis' LDK378 for treatment of patients with anaplastic lymphoma kinase positive metastatic nonsmall-cell lung cancer when crizotinib can't be used. The drug is being tested in two midstage trials, and Novartis plans to initiate several late-stage studies this year. An initial regulatory application is expected early next year.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC